J
Joseph F. Grosso
Researcher at Bristol-Myers Squibb
Publications - 47
Citations - 16375
Joseph F. Grosso is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Ipilimumab. The author has an hindex of 29, co-authored 47 publications receiving 14294 citations. Previous affiliations of Joseph F. Grosso include Johns Hopkins University & University of Miami.
Papers
More filters
Journal ArticleDOI
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer,Scott S. Tykodi,Scott S. Tykodi,Laura Q.M. Chow,Wen-Jen Hwu,Suzanne L. Topalian,Patrick Hwu,Charles G. Drake,Luis H. Camacho,John S. Kauh,Kunle Odunsi,Henry C. Pitot,Omid Hamid,Shailender Bhatia,Renato G. Martins,Keith D. Eaton,Shuming Chen,Theresa M. Salay,Suresh Alaparthy,Joseph F. Grosso,Alan J. Korman,Susan M. Parker,Shruti Agrawal,Stacie M. Goldberg,Drew M. Pardoll,Ashok Kumar Gupta,Jon M. Wigginton +26 more
TL;DR: Antibody-mediated blockade of PD-L1 induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Journal ArticleDOI
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell,Alexander M. Lesokhin,Alexander M. Lesokhin,Ivan Borrello,Ahmad Halwani,Emma C. Scott,Martin Gutierrez,Stephen J. Schuster,Michael Millenson,Deepika Cattry,Gordon J. Freeman,Scott J. Rodig,Bjoern Chapuy,Azra H. Ligon,Lili Zhu,Joseph F. Grosso,Su Y oung Kim,John M. Timmerman,Margaret A. Shipp,Philippe Armand +19 more
TL;DR: Nivolumab had substantial therapeutic activity and an acceptable safety profile in patients with previously heavily treated relapsed or refractory Hodgkin's lymphoma.
Journal ArticleDOI
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng Ryong Woo,Meghan E. Turnis,Monica V. Goldberg,Jaishree Bankoti,Mark J. Selby,Christopher J. Nirschl,Matthew L. Bettini,David M. Gravano,Peter Vogel,Chih Long Liu,Stephanie Tangsombatvisit,Joseph F. Grosso,George J. Netto,Matthew P. Smeltzer,Alcides Chaux,Paul J. Utz,Creg J. Workman,Drew M. Pardoll,Alan J. Korman,Charles G. Drake,Dario A. A. Vignali +20 more
TL;DR: A strong synergy between the PD-1 and LAG-3 inhibitory pathways in tolerance to both self and tumor antigens is defined and it is argued strongly that dual blockade of these molecules represents a promising combinatorial strategy for cancer.
Journal ArticleDOI
Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study
Alexander M. Lesokhin,Alexander M. Lesokhin,Stephen M. Ansell,Philippe Armand,Emma C. Scott,Ahmad Halwani,Martin Gutierrez,Michael Millenson,Adam D. Cohen,Stephen J. Schuster,Daniel Lebovic,Madhav V. Dhodapkar,David Avigan,Bjoern Chapuy,Azra H. Ligon,Gordon J. Freeman,Scott J. Rodig,Deepika Cattry,Lili Zhu,Joseph F. Grosso,M. Brigid Bradley Garelik,Margaret A. Shipp,Ivan Borrello,John M. Timmerman +23 more
TL;DR: Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas and PD-L1/PD-L2 locus integrity and protein expression.
Journal ArticleDOI
Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity
Timothy J. Harris,Joseph F. Grosso,Hung-Rong Yen,Hong Xin,Marcin Kortylewski,Emilia Albesiano,Edward L. Hipkiss,Derese Getnet,Monica V. Goldberg,Charles H. Maris,Franck Housseau,Hua Yu,Drew M. Pardoll,Charles G. Drake +13 more
TL;DR: In vivo evidence is provided that the fundamental role of STAT3 signaling in autoimmunity relates to its absolute requirement for generating TH17 T cell responses, and STAT3 is a candidate target for TH17-dependent autoimmune disease immunotherapy that could selectively inhibit pathogenic immune pathways.